Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19 convalescent and vaccinated plasma refers to plasma collected from individuals who have both recovered from natural SARS-CoV-2 infection and received vaccination against COVID-19. This plasma contains high titers of antibodies against SARS-CoV-2, which can provide passive immunity to recipients through direct viral neutralization and Fc-dependent functions such as phagocytosis, complement activation, and antibody-dependent cellular cytotoxicity. It is most effective when administered early in the disease course and is particularly beneficial for immunocompromised patients who have difficulty mounting their own immune response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on COVID-19 convalescent and vaccinated plasma.